| ATC Class | Antimicrobial | DDD/1,000 inhabitants- days | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BC | AB | SK | MB | ON | QC | NB | NS | PEI | NL | |||
| Roman numerals I to III indicate the ranking of antimicrobials based on importance in human medicine as outlined by the Veterinary Drugs Directorate. ATC = Anatomical Therapeutic Chemical. DDD = Defined daily dose. NPD = No prescriptions dispensed. NC = Not classified. |
||||||||||||
| I | Amoxicillin and enzyme inhibitor | Combinations of penicillins, including ß-lactamase inhibitors (J01CR) | 0.70 | 0.82 | 0.58 | 0.69 | 0.58 | 0.96 | 0.81 | 0.89 | 1.48 | 1.70 |
| Cefixime | Third-generation cephalosporins (J01DD) | 0.08 | 0.06 | 0.02 | 0.04 | 0.08 | 0.05 | 0.05 | 0.08 | 0.30 | 0.17 | |
| Ofloxacin, ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin | Fluoroquinolones (J01MA) | 1.68 | 1.98 | 1.40 | 1.93 | 2.16 | 2.02 | 2.03 | 1.95 | 2.40 | 4.44 | |
| Vancomycin | Glycopeptides (J01XA) | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | |
| Metronidazole | Imidazole (J01XD) | 0.24 | 0.27 | 0.29 | 0.28 | 0.26 | 0.20 | 0.24 | 0.27 | 0.23 | 0.33 | |
| Linezolid | Linezolid (J01XX) | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | |
| II | Ampicillin, amoxicillin, pivampicillin | Penicillins with extended spectrum (J01CA) | 4.01 | 4.69 | 6.94 | 5.59 | 5.21 | 2.85 | 5.06 | 4.87 | 4.94 | 9.09 |
| Penicillin G, penicillin V | ß-lactamase sensitive penicillins (J01CE) | 0.55 | 0.60 | 0.47 | 0.60 | 0.45 | 0.70 | 0.67 | 0.58 | 0.68 | 0.71 | |
| Cloxacillin | ß-lactamase resistant penicillins (J01CF) | 0.17 | 0.16 | 0.35 | 0.45 | 0.16 | 0.13 | 0.15 | 0.20 | 0.19 | 0.38 | |
| Cephalexin, cefadroxil | First-generation cephalosporins (J01DB) | 1.21 | 1.21 | 1.92 | 1.22 | 1.03 | 0.42 | 1.24 | 1.22 | 1.20 | 1.71 | |
| Cefaclor, cefprozil, cefuroxime axetil | Second-generation cephalosporins (J01DC) | 0.56 | 0.62 | 0.38 | 0.49 | 0.87 | 0.78 | 1.68 | 1.15 | 0.43 | 1.43 | |
| Sulfamethoxazole and trimethoprim, sulfadiazine and trimethoprim | Combinations of sulfonamides and trimethoprim, including derivatives (J01EE) | 0.91 | 0.96 | 1.41 | 1.05 | 0.73 | 0.38 | 1.03 | 1.17 | 1.34 | 1.71 | |
| Azithromycin, clarithromycin, erythromycin | Macrolides (J01FA) | 3.35 | 3.90 | 3.09 | 3.32 | 4.13 | 3.40 | 4.20 | 3.95 | 4.66 | 6.22 | |
| Clindamycin | Lincosamides (J01FF) | 0.40 | 0.49 | 0.57 | 0.32 | 0.38 | 0.35 | 0.42 | 0.40 | 0.32 | 0.32 | |
| Tobramycin | Aminoglycosides (J01GB) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | < 0.01 | 0.03 | < 0.01 | NPD | < 0.01 | |
| Nalidixic acid | Other quinolones, excluding fluoroquinolones (J01MB) | NPD | NPD | NPD | NPD | < 0.01 | NPD | NPD | NPD | NPD | NPD | |
| Erythromycin-sulfisoxazole | Sulfonamide combinations, excluding trimethoprim (J01RA) | NPD | NPD | NPD | NPD | NPD | < 0.01 | NPD | NPD | NPD | NPD | |
| Fusidic acid | Steroid antibacterials (J01XC) | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | 0.01 | NPD | |
| III | Doxycycline, minocycline, tetracycline | Tetracyclines (J01AA) | 2.87 | 3.02 | 4.28 | 2.59 | 2.36 | 1.68 | 1.86 | 2.84 | 3.33 | 2.50 |
| Trimethoprim | Trimethoprim and derivatives (J01EA) | 0.04 | 0.03 | 0.11 | 0.01 | 0.06 | 0.05 | 0.05 | 0.02 | 0.01 | 0.11 | |
| Sulfadiazine, sulfamethoxazole | Intermediate-acting sulfonamides (J01EC) | NPD | < 0.01 | NPD | NPD | < 0.01 | NPD | NPD | NPD | NPD | NPD | |
| Nitrofurantoin | Nitrofuran derivatives (J01XE) | 0.68 | 0.61 | 1.04 | 0.47 | 0.83 | 0.32 | 0.74 | 0.97 | 0.75 | 0.60 | |
| Fosfomycin | Fosfomycin (J01XX) | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | NPD | < 0.01 | |
| NC | Methenamine | Methenamine (J01XX) | 0.01 | 0.01 | 0.01 | < 0.01 | < 0.01 | 0.01 | 0.01 | < 0.01 | NPD | < 0.01 |
| Total (J01) | 17.46 | 19.42 | 22.86 | 19.06 | 19.30 | 14.30 | 20.28 | 20.56 | 22.27 | 31.44 | ||